If this update fizzles, I’m not chasing. I’d rather scale in on a pullback with tight stops, maybe pair with some JPM or MA for balance, and only if they show concrete milestones.
Everyone cheering, but I smell another whipsaw.
They’re saying they’re improving timelines and tech, but I’m not convinced. Without specifics, this reads like PR.
So basically shorts are dumping, right?
Feels like every rally gets met with a fresh wave of short squeezes and then a fade. The meme cycle keeps recycling, but fundamentals haven’t changed much. Hard to see sustainable upside without clearer catalysts.
Market feels weirdly split today—meme energy is strong, but everyone’s still nervous about margins and EV demand. If sentiment flips again, we could see another pop, then a quick cool-off before the next leg.
Everyone’s leaning bullish on ENPH after the headline, but I think the market’s overreacting. Regulatory noise doesn’t change the cash burn and pipeline. If they can execute on the new strategy, this could be a quiet, steady drift.
No numbers yet, but last quarter EPS was -$0.12 on $1.2M revenue. Without clear milestones, this pivot feels more PR than progress.
Market loves headlines, forgets fundamentals again.
Market’s overreacting; calm usually follows headlines.
Everyone cheering 'talks going well' vibes, but I’m not buying the bounce. Liquidity’s thin, stops everywhere—watch for fade into any relief rally.
Big commitments suggest durable demand, but execution risk remains. I’m watching margins and lease costs versus revenue growth.
Feels like a big bet on enterprise AI adoption.
If META’s total commitments hit ~$825B, does that mean a 20% revenue bump by 2027? How are you pricing this—$META pop on guidance, or fade into earnings if leases lag? Any better entry than the recent pullback?
With XBI down ~25% this year and biotech beta ~1.8, a 30-40% drop isn’t crazy. If 3/70 pop ~300%, that’s ~4% winners. I’d trim, rebalance, and add cash.
If XBI drops, does momentum chase the winners or just fade biotech? Any names you’re watching for a quick reversal?
300% in biotech sounds like fat-finger math.
